# Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)

> **NCT01065766** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 4065 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin/metformin

## Key facts

- **NCT ID:** NCT01065766
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 4065 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065766, "Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01065766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*